News

Business Wire5y

European Medicines Agency Validates Kite’s Marketing Application for Company’s Second CAR T Cell Therapy

SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), today announced that the company’s Marketing Authorization Application (MAA) for KTE-X19, an investigational chimeric ...
Nasdaq5y

Kite Submits Biologics License Application to U.S. Food and Drug Administration for Company’s Second CAR T Cell Therapy

SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kite, a Gilead Company (Nasdaq: GILD), today announced that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA ...
FierceBiotech10y

Amgen and Kite Pharma Announce Strategic Cancer Immunotherapy Collaboration to Advance the Application of Novel Chimeric Antigen Receptor (CAR) T Cell Therapies

THOUSAND OAKS, Calif. and SANTA MONICA, Calif., Jan. 5, 2015 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Kite Pharma (NASDAQ:KITE) announced today that the two companies have entered into a strategic ...